A Berkeley-born biotech wants to make genetic medicine travel without a viral vector or lipid nanoparticle. Its miniproteins are an elegant delivery idea; the harder test is now scientific and financial.
AI Proteins designs tiny medicines from scratch, then asks its robots whether the molecules can actually do the work. A Bristol Myers Squibb deal shows the appeal; the laboratory still has the last word.